ES2691695T3 - Dispositivos y procedimientos para determinar la función plaquetaria en un analizador centrífugo - Google Patents
Dispositivos y procedimientos para determinar la función plaquetaria en un analizador centrífugo Download PDFInfo
- Publication number
- ES2691695T3 ES2691695T3 ES12158003.9T ES12158003T ES2691695T3 ES 2691695 T3 ES2691695 T3 ES 2691695T3 ES 12158003 T ES12158003 T ES 12158003T ES 2691695 T3 ES2691695 T3 ES 2691695T3
- Authority
- ES
- Spain
- Prior art keywords
- chamber
- subarea
- measuring cell
- liquid
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 27
- 210000004027 cell Anatomy 0.000 claims abstract description 126
- 210000001772 blood platelet Anatomy 0.000 claims abstract description 121
- 239000007788 liquid Substances 0.000 claims abstract description 107
- 238000005259 measurement Methods 0.000 claims abstract description 52
- 239000000126 substance Substances 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 22
- 239000000463 material Substances 0.000 claims description 11
- 239000011148 porous material Substances 0.000 claims description 11
- 238000004891 communication Methods 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 239000012190 activator Substances 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 7
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 7
- 229960005139 epinephrine Drugs 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 6
- 125000006850 spacer group Chemical group 0.000 claims description 6
- 238000004599 local-density approximation Methods 0.000 claims description 5
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 108010081391 Ristocetin Proteins 0.000 claims description 3
- 108090000190 Thrombin Proteins 0.000 claims description 3
- WLMZTKAZJUWXCB-KQYNXXCUSA-N [(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O WLMZTKAZJUWXCB-KQYNXXCUSA-N 0.000 claims description 3
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 claims description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 claims description 3
- 229950004257 ristocetin Drugs 0.000 claims description 3
- 229940076279 serotonin Drugs 0.000 claims description 3
- 229960004072 thrombin Drugs 0.000 claims description 3
- LQANGKSBLPMBTJ-BRSNVKEHSA-N (z)-7-[(1s,2s,3r,4r)-3-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid Chemical compound C1[C@@H]2CO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O LQANGKSBLPMBTJ-BRSNVKEHSA-N 0.000 claims description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 2
- 229940114079 arachidonic acid Drugs 0.000 claims description 2
- 235000021342 arachidonic acid Nutrition 0.000 claims description 2
- ARUGKOZUKWAXDS-SEWALLKFSA-N cicaprost Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 claims description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 2
- 229960005188 collagen Drugs 0.000 claims description 2
- 229960001123 epoprostenol Drugs 0.000 claims description 2
- 229960002240 iloprost Drugs 0.000 claims description 2
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical group CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229950000634 cicaprost Drugs 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 1
- 239000000523 sample Substances 0.000 description 95
- 239000008280 blood Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 20
- 238000004220 aggregation Methods 0.000 description 15
- 230000002776 aggregation Effects 0.000 description 15
- 208000032843 Hemorrhage Diseases 0.000 description 11
- 210000004623 platelet-rich plasma Anatomy 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000023597 hemostasis Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 8
- 230000000740 bleeding effect Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000004308 accommodation Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000015271 coagulation Effects 0.000 description 6
- 238000005345 coagulation Methods 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000013167 light transmission aggregometry Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003790 Thrombin receptors Human genes 0.000 description 2
- 108090000166 Thrombin receptors Proteins 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003705 antithrombocytic agent Substances 0.000 description 2
- 208000015294 blood coagulation disease Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960003009 clopidogrel Drugs 0.000 description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
- 230000009852 coagulant defect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960005001 ticlopidine Drugs 0.000 description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
- 239000012780 transparent material Substances 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- -1 yagina Proteins 0.000 description 2
- XBPBJFWGYUJISD-IUCAKERBSA-N (4s)-4-amino-5-[[2-[[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]amino]acetyl]amino]-5-oxopentanoic acid Chemical compound OC(=O)CC[C@H](N)C(=O)NC(=O)CN[C@H](C(=O)CCl)CCCN=C(N)N XBPBJFWGYUJISD-IUCAKERBSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- VNDNKFJKUBLYQB-UHFFFAOYSA-N 2-(4-amino-6-chloro-5-oxohexyl)guanidine Chemical compound ClCC(=O)C(N)CCCN=C(N)N VNDNKFJKUBLYQB-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- 101710163968 Antistasin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 206010020608 Hypercoagulation Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 108010061260 draculin Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 description 1
- 229960002137 melagatran Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000000615 nonconductor Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000009076 regulation of hemostasis Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940125670 thienopyridine Drugs 0.000 description 1
- 239000002175 thienopyridine Substances 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 108010065972 tick anticoagulant peptide Proteins 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5021—Test tubes specially adapted for centrifugation purposes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0409—Moving fluids with specific forces or mechanical means specific forces centrifugal forces
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11158195A EP2500095A1 (de) | 2011-03-15 | 2011-03-15 | Vorrichtungen und Verfahren zur Bestimmung der Plättchenfunktion in einem Zentrifugalanalyzer |
| EP11158195 | 2011-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2691695T3 true ES2691695T3 (es) | 2018-11-28 |
Family
ID=44359752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12158003.9T Active ES2691695T3 (es) | 2011-03-15 | 2012-03-05 | Dispositivos y procedimientos para determinar la función plaquetaria en un analizador centrífugo |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9205424B2 (enExample) |
| EP (2) | EP2500095A1 (enExample) |
| JP (1) | JP5860736B2 (enExample) |
| CN (1) | CN102759614B (enExample) |
| ES (1) | ES2691695T3 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8617468B2 (en) | 2011-10-18 | 2013-12-31 | Chrono-Log Corporation | Platelet aggregation test and device |
| JP6012455B2 (ja) * | 2012-12-21 | 2016-10-25 | シーメンス ヘルスケア ダイアグノスティクス プロダクツ ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 血小板機能を測定するシステムにおいて測定結果を標準化する方法 |
| KR101497193B1 (ko) * | 2012-12-31 | 2015-03-03 | 고려대학교 산학협력단 | 원심력 미세유동 기반 혈소판 복합기능 및 약물반응 검사 장치 및 방법 |
| CN204182492U (zh) * | 2013-12-05 | 2015-03-04 | 刘玥萌 | 一种离心过滤管 |
| CN104359746B (zh) * | 2014-11-19 | 2018-03-16 | 白银市第一人民医院 | 细胞团块收集器及收集体液标本中细胞的方法 |
| CN110095521B (zh) | 2019-05-13 | 2022-08-23 | 京东方科技集团股份有限公司 | 离心管、检测系统及检测方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5256993A (en) * | 1975-10-31 | 1977-05-10 | Jiometsuto Inc | Method of and instrument for measuring solidifying rate |
| JPS5889859U (ja) * | 1981-12-11 | 1983-06-17 | 東亜医用電子株式会社 | 凝固時間測定具 |
| DE3247815C2 (de) * | 1982-12-23 | 1985-10-17 | Gustav Viktor Rudolf Prof. London Born | Einrichtung zur Messung der Blutungszeit in vitro |
| GB2175691A (en) | 1985-04-26 | 1986-12-03 | Brien John Richard O | Bleeding time measurement |
| DE3739247C2 (de) * | 1987-11-19 | 1996-11-21 | Dade Int Inc | Blutungszeitmeßeinrichtung |
| DE69523722T2 (de) | 1994-06-30 | 2002-08-01 | Dade Behring Inc., Deerfield | Bioaktive poröse trennteile |
| US5888826A (en) * | 1994-06-30 | 1999-03-30 | Dade Behring Inc. | Combination reagent holding and test device |
| DE59608443D1 (de) * | 1996-03-18 | 2002-01-24 | Diagnostische Forsch Stiftung | Partikel-Immunoassay mit kompakter Matrix |
| JP3743918B2 (ja) | 1996-03-22 | 2006-02-08 | デイド、ベーリング、インコーポレイテッド | コンビネーション試薬保持およびテスト装置 |
| US20120156278A1 (en) * | 1997-06-24 | 2012-06-21 | Cascade Medical Enterprises, Llc | Systems and methods for preparing autologous fibrin glue |
| US7087177B2 (en) | 2004-04-16 | 2006-08-08 | Baxter International Inc. | Methods for determining flow rates of biological fluids |
| WO2006086201A2 (en) * | 2005-02-07 | 2006-08-17 | Hanuman Llc | Platelet rich plasma concentrate apparatus and method |
| EP1693109A1 (de) | 2005-02-21 | 2006-08-23 | Hexal Ag | Behältnis zur Separation von Tumorzellen |
| CN100467075C (zh) * | 2005-08-09 | 2009-03-11 | 郭经纬 | 一种多向离心式连续性血液成分分离设备 |
| US20070102374A1 (en) | 2005-11-04 | 2007-05-10 | Gambro, Inc. | Blood processing apparatus with controlled cell capture chamber and method background of the invention |
| CN100429517C (zh) * | 2006-09-29 | 2008-10-29 | 暨南大学 | 筛选中药抗血小板聚集作用活性成分的细胞膜固相色谱法模型的建立方法 |
| EP2053387A1 (en) * | 2007-10-22 | 2009-04-29 | Centre National de la Recherche Scientifique | Test device for platelet aggregation detection |
| US8187475B2 (en) * | 2009-03-06 | 2012-05-29 | Biomet Biologics, Llc | Method and apparatus for producing autologous thrombin |
-
2011
- 2011-03-15 EP EP11158195A patent/EP2500095A1/de not_active Withdrawn
-
2012
- 2012-03-05 EP EP12158003.9A patent/EP2500096B1/de active Active
- 2012-03-05 ES ES12158003.9T patent/ES2691695T3/es active Active
- 2012-03-14 JP JP2012057627A patent/JP5860736B2/ja active Active
- 2012-03-15 CN CN201210068133.3A patent/CN102759614B/zh active Active
- 2012-03-15 US US13/421,468 patent/US9205424B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2500096B1 (de) | 2018-07-18 |
| JP5860736B2 (ja) | 2016-02-16 |
| JP2012194181A (ja) | 2012-10-11 |
| US9205424B2 (en) | 2015-12-08 |
| CN102759614A (zh) | 2012-10-31 |
| EP2500096A1 (de) | 2012-09-19 |
| US20120237960A1 (en) | 2012-09-20 |
| EP2500095A1 (de) | 2012-09-19 |
| CN102759614B (zh) | 2017-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2691695T3 (es) | Dispositivos y procedimientos para determinar la función plaquetaria en un analizador centrífugo | |
| US8895259B2 (en) | Method for determination of platelet function under flow conditions | |
| JP4989292B2 (ja) | 血小板機能の流動状態下での測定方法および装置 | |
| JP5937612B2 (ja) | 血液安定剤を含む採血用デバイス | |
| CA2340365C (en) | Novel method of platelet function analysis using platelet count | |
| US7071001B2 (en) | System and method for in vitro bleeding time testing | |
| CN106164669A (zh) | 血液状况分析装置、血液状况分析系统、血液状况分析方法和用于使计算机实现该方法的血液状况分析程序 | |
| CA2490432A1 (en) | Cartridge for monitoring the function of a device for testing blood platelet function, method for function monitoring, and use of a test fluid | |
| ES2635196T3 (es) | Controles y kit para ensayos de actividad plaquetaria | |
| JP6596768B2 (ja) | 血液性状検査用マイクロチップおよび血液性状検査用装置 | |
| EP0876618B1 (en) | Blood factor assay | |
| BR102015005628A2 (pt) | composição, e, uso de ácido ferúlico | |
| ES2524867T3 (es) | Método para la estandarización de resultados de medición en un sistema para la medición de la función de los trombocitos | |
| JP6012455B2 (ja) | 血小板機能を測定するシステムにおいて測定結果を標準化する方法 | |
| FI59679C (fi) | Foerfarande och anordning foer maetning av koaguleringshastigheten hos en vaetska | |
| WO2021145787A1 (ru) | Способ и устройство для определения степени гидродинамической активации фактора фон виллебранда | |
| EP1600777A2 (en) | A single-tube method and system for platelet function analysis |